BOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, ...

BOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, ...

Praxis Precision Medicines remains a Hold as valuation now reflects high expectations for ulixacaltamide and its epilepsy pipeline. Ulixacaltamide’s Essential3 data appear statistically robust, but a ...

Praxis Precision Medicines has won Food and Drug Administration breakthrough-therapy designation for its ulixacaltamide drug candidate for the treatment of patients with essential tremor. Praxis on ...

Sen. Dwayne T.D. San Nicolas on Wednesday introduced Bill 282-37, which seeks to remove the Praxis mathematics requirement from the Guam initial educator certificate, saying this would address the ...

Sen. Dwayne T.D. San Nicolas' Bill 282-37, which seeks to remove the Praxis core mathematics requirement from the Guam Educator Certification, drew support during a May 22 hearing. “I do not want to ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. More than 25% of the UC San Diego students placed in the school's lowest remedial math class ...

Praxis Precision Medicines (PRAX) just hit a double inflection point, with its EMBOLD trial for relutrigine stopped early for efficacy and a successful pre-NDA meeting for ulixacaltamide setting up a ...

Praxis Precision Medicines Inc. (NASDAQ: PRAX) shares surged 24.81% in pre-market trading on Friday, climbing to $237.10. Check out the current price of PRAX stock here. PRAX closed Thursday's regular ...

Investing.com -- Praxis Precision Medicines (NASDAQ:PRAX) stock dropped 4% on Thursday following the release of a critical short report from Culper Research questioning the company’s Phase 3 trial ...

For the past several years, America has been using its young people as lab rats in a sweeping, if not exactly thought-out, education experiment. Schools across the country have been lowering standards ...

Seven months ago, independent clinical trial observers peeked at interim data for Praxis Precision Medicines’ essential tremor drug and recommended stopping the Phase 3 studies. Praxis kept going. On ...